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The malignant myeloid diseases discussed in this section are clonal disorders of hematopoietic stem cells (HSCs) and progenitor cells with various underlying molecular basis, different clinical phenotypes and largely differing 
prognosis. Although younger patients may be affected, these dis-
orders mainly occur in older individuals, with median ages of 
patients ranging from 55 to 60 years in chronic myeloid leuke-
mia (CML) to approximately 75 years in myelodysplastic syn-
dromes (MDS). Thus, malignant myeloid disorders represent an 
increasing burden for healthcare systems in an aging population.
In recent years, major advances have been made in the under-
standing of the molecular basis of malignant myeloid disorders, 
in particular with the advent of the next-generation sequencing 
technologies. European researchers have been leading and were 
involved in pivotal studies deciphering single disease genes, such 
as JAK2 or CALR mutations in myeloproliferative neoplasms 
(MPNs) or entire molecular disease landscapes. Recent studies 
have provided evidence that some of these gene mutations asso-
ciated with malignant myeloid disease are commonly acquired 
in HSCs during aging, a phenomenon that was termed “clonal 
hematopoiesis of indeterminate potential“ (CHIP) or “age-re-
lated clonal hematopoiesis“ (ARCH). CHIP has been associated 
with malignant myeloid diseases, but also with an increased risk 
of cardiovascular diseases and decreased overall survival.
The better understanding of the molecular basis has paved the 
way for precision medicine approaches in malignant myeloid 
disorders. This is exemplified by the successful development 
of FLT3-, IDH1/IDH2-, or BCL-2 inhibitors in acute myeloid 
leukemia (AML), of next-generation tyrosine kinase inhibitors 
in CML, or of JAK2-inhibitors in MPN. European research in 
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hematology has a long-standing tradition of well-organized clin-
ical trial groups conducting well-designed pivotal phase 3 stud-
ies, thereby making major contributions to this development.
Under the umbrella of the European LeukemiaNet (ELN) 
and the European Hematology Association (EHA), European 
researchers—in collaboration with other international 
experts—have published a wealth of recommendations and 
guideline papers that have been highly valuable for the scien-
tific community, patients, care givers, and also for regulatory 
authorities.
Nevertheless, major challenges remain in improving out-
comes and quality of life for patients with malignant myeloid 
diseases. One challenge relates to the enormous (epi)-genomic 
complexity of most of these disorders, with multiple epigenetic 
lesions being present at diagnosis, and subsequent clonal evolu-
tion over the disease course with various mechanisms of resis-
tance. Thus, overcoming primary and/or secondary resistance 
to conventional as well as targeted agents will be a major task 
in this Research Roadmap. Another hurdle relates to challenges 
in future clinical trial design. Malignant myeloid disorders in 
general are rare diseases, and with the development of precision 
medicine in molecular subgroups, the conduct of pivotal phase 
3 studies has become challenging. Thus, a joint European and 
intercontinental effort—in close collaboration with important 
stakeholders such as patient advocacy groups, biotech and phar-
maceutical industry—will be necessary to expedite the develop-
ment of new therapies for our patients.
MDSs and myelodysplastic/MPNs
Introduction
The MDSs are clonal disorders of HSC which are charac-
terized by peripheral blood cytopenia, dysplasia in one or 
more myeloid cell lines, and a propensity to evolve into AML. 
Myelodysplasia is not restricted to MDS but may be found also 
in other myeloid neoplasms, in particular in the so-called MDS/
MPN, which mainly include chronic myelomonocytic leukemia 
and less frequent diseases, including atypical CML, chronic neu-
trophilic leukemia, juvenile myelomonocytic leukemia, MDS/
MPN with ring sideroblasts, and thrombocytosis.
The crude incidence rate of MDS is 4 per 100,000 people per 
year, but increases up to 50 per 100,000 persons per year over 
the age of 60, indicating that >30,000 new cases are expected 
in Europe each year and making MDS one of the most common 
hematologic malignancies in Western countries. Furthermore, 
recent data suggest that this incidence may be significantly 
underestimated, because many MDS patients may remain 
underdiagnosed as anemia or cytopenia of the elderly.
MDSs are caused by somatic mutations that occur in HSC, 
conferring a proliferative advantage to HSC while inducing 
ineffective differentiation and maturation of hematopoietic 
progenitor cells resulting in peripheral blood cytopenia.2–6 
Recent studies provided evidence that somatic mutations in 
some of the genes frequently mutated in MDS are commonly 
acquired in HSC during aging, and that apparently normal sub-
jects with these mutations have increased risk of hematologic 
malignancies and increased cardiovascular and all-cause mor-
tality (ARCH or CHIP).
MDS and MDS/MPN show marked clinical heterogeneity, 
ranging from conditions with an indolent clinical course and 
a near-normal life expectancy to entities with very poor prog-
nosis. A risk-adapted treatment strategy is therefore mandatory 
for these disorders. At present, the only treatment with a poten-
tially curative effect is allogeneic HSC transplantation (HSCT). 
Azacitidine can prolong survival in patients with high-risk 
MDS, while erythropoiesis-stimulating agents and lenalidomide 
improve anemia in patients with low-risk MDS and the MDS 
associated with deletion 5q, respectively.7,8 More recently, lus-
patercept has been proven effective in reducing transfusion bur-
den in MDS with ring sideroblasts.9 Chronic red cell transfusion 
remains the mainstay of therapy for many patients with MDS.
European research contributions
In the past few years, major advances in the understanding of 
the genetic basis of MDS have been made by means of massive 
parallel DNA sequencing, and a number of seminal studies have 
been performed in Europe.2–6
Approximately, 90% of MDS patients carry one or more 
oncogenic mutations with two-thirds of them are found in indi-
viduals with a normal karyotype. Driver mutations have been 
identified in genes involved in RNA splicing, DNA methylation, 
chromatin modification, transcription regulation, DNA repair, 
and signal transduction. Only a few genes are consistently 
mutated in 10% or more MDS patients, including those involved 
in epigenetic regulation (TET2, ASXL1, and DNMT3A) and 
splicing factors (SF3B1, SRSF2, and U2AF1), while a long tail 
of >50 genes are mutated less frequently.3,4 Mutations in SF3B1 
have been found to be highly specific for MDS with ring sidero-
blasts and are associated with a very low risk of disease progres-
sion and a favorable outcome.5
European hematologists have provided pivotal contribu-
tions to developing effective treatments for MDS, including 
erythropoietin, azacitidine, lenalidomide, and luspatercept.7–9 
Recommendations for treatment of the individual patient with 
MDS, including allogeneic HSCT, have also been developed in 
recent years.10–12
Seminal contributions have also been made in pediatric hema-
tology, for example, in elucidating the genetic predisposition to 
juvenile myelomonocytic leukemia, as well as to MDS or other 
myeloid neoplasms.13
Proposed research for the Roadmap
Myeloid malignancies appear to be propagated by rare 
self-renewing mutant HSCs. However, the cellular and molec-
ular mechanisms that regulate development, propagation, and 
therapy resistance of these myelodysplastic stem cells remain 
unknown. Studies are needed to:
1. characterize cellular and molecular mechanisms involved 
in disease development, progression and therapy resistance, 
including germline predisposition, chronic inflammation, 
microenvironmental and immunological abnormalities, as 
well as immune escape following stem cell transplantation;
2. identify premalignant conditions associated with increased 
risk to develop MDS and MDS/MPN and recognize the 
interaction of hematopoietic clones with multimorbidities 
and complex chronic conditions in older persons;
3. identify therapeutic targets for efficient elimination of the 
MDS-propagating cells and establish suitable frameworks 
for biology-driven clinical trials.
While recent advances have shed light on the genetic complex-
ity of MDS paving the way for precision medicine strategies, the 
factors enabling the emergence, selection, and subsequent leuke-
mic evolution of these clones remain incompletely understood. 
Single-cell studies combining analysis of the genome and tran-
scriptome as well as preclinical models are warranted to iden-
tify the impact of recurrent molecular abnormalities on gene 
expression, to detect the deviation of mutant cells from their 
normal counterpart, and to identify mesenchymal niche abnor-
malities and disrupted signaling contributing to the occurrence 
of somatic mutations, their selection, and subsequent clonal 
expansion.14 Systematic studies of comprehensive mutational 
profiling of germline and somatic mutations within the frame 
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of population-based registries and clinical trials are required to 
define the clinical implications of mutation profiles in unbiased 
and homogeneously treated patient populations.
Studies aimed at characterizing CHIP and identifying intra-
clonal and extraclonal variables associated with progression 
into overt malignancy are required and will pave the way to 
early diagnosis and pre-emptive interventions. Emerging data 
are pointing toward a strong interaction of myelodysplastic 
clones with age-related chronic inflammation, as well as with 
multimorbidities and complex chronic conditions. Population-
based studies that analyze the relationships between clonal 
hematopoiesis and its genetic drivers, gender, age, and comor-
bidities are needed.
Outcome improvements in MDS patients remain modest. 
Identifying therapeutic agents that may further improve survival 
and quality of life of patients with MDS represents a priority. 
Promising strategies include combination treatment containing 
azacitidine in high-risk MDS (including BCL-2 inhibitors), and 
drugs that inhibit ineffective erythropoiesis and improve ane-
mia in those with low-risk MDS. Novel drugs targeting molec-
ular abnormalities, including spliceosome, epigenetic regulators 
(particularly IDH1 and IDH2), and TP53 mutations, are cur-
rently under investigation and should be further developed. 
Establishing suitable frames for biology-driven clinical trials is 
needed, and patient inclusion in clinical trials should be encour-
aged. Reducing the toxicity of allogeneic HSCT in MDS and 
MDS/MPN elderly population will be critical to allow more 
patients to benefit from the procedure. More effective transplan-
tation procedures integrating biology-driven pretransplant and 
posttransplant should be developed.
Anticipated impact of research
The current lack of understanding the molecular mechanisms 
that regulate MDS stem cell expansion and their escape from 
therapeutic and immunological targeting is limiting our abil-
ity to efficiently eradicate these disorders. The research lines 
described above have the potential to decipher these mecha-
nisms and identify suitable targets for effective intervention.
The identification of premalignant conditions with no or mild 
clinical expressivity will allow to develop effective strategies of 
early diagnosis and intervention aimed at preventing clonal 
expansion and progression.
The characterization of genomic and transcriptomic pro-
files of each individual patient with MDS or MDS/MPN will 
allow the most appropriate treatment to be selected, patients to 
be enrolled in ad hoc clinical trials investigating new targeted 
therapeutic agents, and molecular biomarkers for monitoring 
response to treatment to be identified. This will eventually lead 
to precision medicine strategies.
Acute myeloid leukemia
Introduction
Acute myeloid leukemia (AML) is the most common form 
of acute leukemia in adults with an estimated incidence of 
3.7 per 100,000 individuals, resulting in 17,000 newly diag-
nosed patients each year in Europe. The incidence rises with 
age (median age is 70 y) implicating a further rise in future 
years.15 This is a clonal disorder arising from hematopoietic 
progenitor cells characterized by defects in their maturation 
program resulting in uncontrolled proliferation and subsequent 
bone marrow failure. Genomic techniques have unraveled the 
molecular complexity of AML that guided refinement of risk 
stratification and personalized therapeutic strategies for AML 
patients.16,17 The prognosis is poor with cure rates of 40%–50% 
in the younger population decreasing to <10%–15% in the 
elderly. Until recently, therapeutic options were mostly limited 
to cytotoxic chemotherapy. Increased donor availability coupled 
with the advent of reduced intensity conditioning regimens has 
led to allogeneic HSCT becoming an increasingly important 
potentially curative treatment strategy.18
However, there has been an explosion of newly approved 
drugs since 2017, with the majority of them targeting specific 
gene mutations and/or pivotal cell survival pathways.19 These 
novel agents have been tested mainly in older patients with 
comorbidities and/or relapsed/refractory disease, in whom the 
treatment of choice is limited and the clinical outcome is very 
poor. Recently, the combination of venetoclax and azacitidine 
(Ven/Aza) has been shown to improve survival in elderly AML 
patients.20 At the same time, increased donor availability cou-
pled with the advent of reduced intensity conditioning regimens 
has led to allogeneic HSCT becoming an increasingly important 
potentially curative treatment strategy.18
European research contributions
Europe has a longstanding tradition in performing well-de-
signed phase 3 studies by experienced and well-organized 
AML trial groups. Until recently, these studies were mainly per-
formed in all comers investigating new drugs in combination 
with the 3+7 backbone already standard of care for decades. 
Reduced intensity conditioning regimens, graft-versus-host 
disease prophylaxis and posttransplant interventions in allo-
geneic HSCT all have contributed to the better outcome of 
AML. Now since druggable genetic biomarkers are identified 
and new targeted drugs have become available, more targeted 
trials will be conducted.19 Given this segregation, collaboration 
between European trial groups are required if the delivery of 
practice informing trials of new drug and transplant therapies is 
to be accelerated. Already a combined effort of European trial 
groups has resulted in the approval of a drug targeting CD33: 
Gemtuzumab Ozogamycin.21 Another major achievement is the 
successful development of a chemotherapy-free regimen in acute 
promyelocytic leukemia (APL) with cure rates >95% in low- 
and intermediate-risk APL.22
The internationally embraced ELN recommendations on the 
diagnosis and management of AML now plays a pivotal role 
in the management of AML internationally having transformed 
clinical practice.18 The European concept of the assessment of 
measurable residual disease (MRD) has significantly improved 
the management of AML. The ELN recommendation on MRD 
plays an important role in harmonization and standardization 
of flow cytometric and molecular techniques for MRD monitor-
ing, resulted in the development of new clinical guidelines and 
informed decision making by regulatory authorities including 
the FDA and EMA.23
New insights in the biology of AML with mutated, trans-
located, or overexpressed genes, like NPM1, PML-RARA, 
CEBPA, MECOM (EVI1), and germ-like mutations, predis-
posing to the development of AML have been identified by 
European investigators.17
Proposed research for the Roadmap
Collaboration between basic, translational, and clinical 
hematologists will be required to generate continuous major 
progress in the next years.
Given the molecular heterogeneity underlying AML, large 
cohorts need to be analyzed to better capture how genetic aber-
rations can affect treatment outcome.16 Within the HARMONY 
Alliance, a large pan-European public–private partnership 
funded through the Innovative Medicines Initiative (IMI), a 
large “Big Data for Better Outcome” platform for AML has 
been built with the aim to put together at least 10,000 cases 
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of AML (https://www.harmony-alliance.eu/). Gene–gene inter-
actions analysis will detect new patterns of co-occurrence and 
mutual exclusivity and correlation with clinical outcome will 
provide significant information on treatment and course of the 
disease. Genomic analysis of single cells will lead to a better 
understanding of the multiclonal diversity of AML at diagnosis 
and during evolution.24
Further standardization and development of MRD techniques 
to increase sensitivity, making use of peripheral blood instead of 
bone marrow, automatic analysis, is work in progress in the ELN 
MRD Working Party.23 Apart from the already established value 
of diagnosis next-generation sequencing should additionally be 
explored for MRD detection; here, gene panels will also allow to 
further elucidating clonal evolution and resistance in serial analy-
sis.25 In addition, studies to convert MRD positivity to negativity 
pretransplant have to be done as well as studies addressing the 
question that MRD apart from prognostic value also has predic-
tive value in order to be accepted as surrogate for survival.26
Certain genetic and molecular defined AMLs (eg, TP53mut, 
monosomal karyotype, ASXL1mut, and RUNX1mut) are associ-
ated with a poor prognosis.16 New therapeutic strategies/drugs 
should be investigated in these AML subtypes. Also AMLs with 
druggable mutations (eg, FLT3mut and IDHmut) should be investi-
gated in separate trials either by adding new drugs to a 7+3 back-
bone or in combinations or triplets based on the good results 
with the combination Ven/Aza.20,27 Because these are only small 
subgroups, these research questions only can be accomplished 
by collaborations between all the major trial groups in Europe. 
Because relapse after transplantation is still an important cause 
of failure after the most effective antileukemic treatment, strat-
egies to reduce the risk of relapse rate posttransplantation are 
urgently needed and are currently being examined through pro-
spective randomized trials led by European groups.
The role of maintenance treatment should be explored. 
Recently, CC-486, an oral hypomethylating agent, applied as 
maintenance has been shown to improve overall survival in 
elderly patients in CR/CRi not suitable for transplantation.28 
Maintenance treatment should be studied by appropriate deliv-
ery of immunotherapy, hypomethylating agents, and targeted 
small molecules in remission.
The promising impact of immunotherapy (eg, armed antibod-
ies, bispecific antibodies, vaccines, immune checkpoint inhibi-
tors, and CAR-T cells) should be intensively explored.
At the same time, we need a better understanding of mecha-
nisms of leukemic stem/progenitor resistance to classical chemo-
therapy and targeted agents, an area where European scientific 
programs excel. A better understanding and characterization of 
leukemic stem/progenitor cells, the impact of the clonal archi-
tecture of leukemia, and the clonal evolution during the disease 
course should pave the way to target them.
Finally, we are now improving not only curing patients but 
also extending survival without cure. Quality of life issues have 
been neglected in AML, and have more recently become more 
and more relevant and should become part of our research 
agenda and each clinical trial.
Anticipated impact of the research
The proposed research aims at further deciphering the com-
plex molecular heterogeneity of myeloid diseases, which ulti-
mately will result in further refinement of this disease. Big data 
mining will be instrumental for detecting gene–gene interac-
tions, performing automatic analysis of MRD and developing 
personalized treatment.
The heterogenous clonal architecture of the disease suggests 
that most likely no single drug is expected to cure AML. Rather, 
the combination of classical standard chemotherapy with novel 
agents or combinations of novel agents are expected to improve the 
outcome. Accelerated delivery of prospective transplant trials will 
also provide insights into strategies to improve transplant outcome. 
Special attention must also be paid to the better management of 
older patients, given the more unfavorable and distinct biology and 
the still dismal outcome of the disease in these patients.
The proposed research directions are expected to provide 




Chronic myeloid leukemia (CML) is a neoplastic disease of 
HSCs. CML is typically linked to the Philadelphia Chromosome, 
a shortened chromosome 22 as the result of a reciprocal translo-
cation of chromosomes 9 and 22 leading to fusion of BCR and 
ABL1 genes. CML constitutes about 15% of all leukemias and 
occurs with an incidence of about 1.2/100,000. CML went along 
with an almost fatal outcome until 20 years ago. Through the 
excellent results of BCR-ABL1 tyrosine kinase inhibitor (TKI) 
treatment, most CML patients face an excellent prognosis.29–31 
Currently, about 10%–20% of patients will achieve a condition 
of treatment-free remission (TFR). The use of interferon alpha 
(IFN) in parallel with or after TKI therapy could be associated 
with the induction of an immune response against the leukemic 
clone with further improvement of the remission rate. The essen-
tial part of the management of CML patients is a rigorous use of 
standardized surveillance methods to regularly assess the resid-
ual disease status. Adverse events should be prevented by indi-
vidual selection of therapy according to patients’ risk profiles. 
Patients’ advocacy groups have become partner organizations in 
education, clinical practice and research. Prevalence of patients 
with CML treated with TKIs is steadily increasing, which is a 
challenge for healthcare systems worldwide. The main task is 
to optimize treatment for patients’ maximum benefit with an 
affordable allocation of the resources.
European research contributions
European cooperative CML study groups have been estab-
lished 30–40 years ago and have continuously contributed to 
the optimization of management. The impact of IFN has been 
investigated in a series of large studies. IFN as an immunomod-
ulatory agent has activity in CML and has resulted in sustained 
cytogenetic remissions in an important minority of patients.29 
Meta-analyses between conflicting studies revealed new prog-
nostic factors for IFN response. The place of allogeneic HSCT in 
disease management had been gradually evolving, having been 
displaced as the first-line treatment by 2002, and then moving 
to a third or fourth line option after the licensing of the sec-
ond-generation TKIs in 2006. From 2001, European investi-
gators have participated in the clinical development of 6 TKIs. 
National and multinational (ELN) networks of European CML 
investigators and clinicians have produced fundamental knowl-
edge for clinical practice.31–34 Cooperative studies have contrib-
uted to the understanding of the biology of TKI response. In 
addition, the impact of combination therapies and baseline and 
time dependent prognostic factors contributed. As a result of a 
study of the ELN involving >5000 patients, a new score predict-
ing the CML-specific survival on TKI therapy was established.32 
The predictive value of early molecular response, deep molecu-
lar response, and the velocity of response has been identified in 
Europe. ELN expert recommendations for CML management 
published in 2006, 2009, 2013, and 2020 and have become a 
key reference for CML treatment worldwide.31
In basic and translational research, European investigators 
significantly contributed to the understanding of the mechanisms 
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of TKI resistance and how to prevent and overcome it.34 
Molecular monitoring of CML has been developed, optimized, 
and standardized in Europe, allowing accurate quantification of 
residual disease in a dynamic range of 6 orders of magnitude. 
Such contribution permitted the successful attempt to discon-
tinue treatment after deep molecular response.33,35 Currently, 
biology of persistence of BCR-ABL1 positive stem cells has been 
a major focus of research. Other research directions include the 
origin of CML, the clonal molecular evolution, and the charac-
terization of the BCR-ABL1 negative hematopoiesis.
Proposed research for the Roadmap
TKIs have substantially improved the survival of CML 
patients. There is reasonable expectancy to cure the disease in 
a significant proportion of patients. The main objective is to 
integrate the leading European national trial groups in CML 
to form a cooperative network for advancements in CML 
related research and health care. Within the group of European 
Investigators on CML (EICML), a clinical trials platform was 
created to promote the performance of clinical trials with new 
drugs and/or treatment strategies. Standardization of diagnostic 
and therapeutic procedures allows outcome comparison across 
Europe. We aim to improve (1) tolerability of the treatment; (2) 
the rate of deep molecular response; and (3) the rate of patients 
in durable remission after stopping TKI. Enhanced inhibition of 
BCR-ABL1 with more specific inhibitors or drug combinations 
are possible strategies to improve TFR by increasing the rates of 
deep molecular response.36 Clinical approaches utilizing immune 
surveillance to eradicate residual leukemic cells are potential 
future research directions to improve TFR rates. Despite major 
improvement in the standard of care for CML, the complexity 
of CML blast crisis pathophysiology, together with the failure 
of TKIs to eradicate CML at the stem cell level, as well as the 
observation of molecularly defined BCR-ABL1 negative clones 
demand further research. A better understanding of the events 
governing leukemic stem cell behavior might lead to the bio-
logical cure of CML and effective treatment of blast crisis. 
Current efforts continue to uncover new pathways involved in 
BCR-ABL1 independent TKI resistance. Inhibition of BCL2 and 
MEK, for example, both showed promise in preclinical models 
awaiting and testing in clinical trials. Translational studies will 
contribute to early outcome prediction and treatment surveil-
lance. Establishing preclinical models that more faithfully reflect 
human CML and its progression to blast phase, along with sim-
plifying clinical trials will also be critical for progress in this 
area. Biostatisticians and patient advocacy groups cooperate 
with the study groups with a European clinical trials platform 
which will support the coordination of the studies.
Research Agenda:
• Increasing the rate of TFR;
• Overcoming TKI resistance in patients with multi-TKI 
failure;
• Improving outcomes for patients with accelerated and blast 
phase CML;
• Developing better animal models that more faithfully reca-
pitulate features of human CML;
• Preventing cardiovascular toxicity associated with second- 
and third-generation TKIs.
Anticipated impact of research
A more in-depth molecular and cellular characterization of 
CML patients might facilitate personalized medicine regard-
ing diagnosis, prognostication, and therapeutic decisions. 
Overall, this will have a major impact in lowering the disease 
burden, reducing the rate of complications and, prospectively, 
prolonging survival. The cost of novel technologies and treat-
ments might be balanced by their more specific application as 
well as a favorable impact on the patients’ quality of life and the 
lessened burden for caregivers; this will translate into a more 
general favorable impact for the society in general by reducing 
use of resources and improving individual work capabilities. 
Standardization of diagnostics and therapeutic procedures will 
further strengthen integration. The thereby achieved compara-
bility of outcome will facilitate recognition of interstudy differ-
ences and rare subtypes. Recommendations, network meetings, 
training courses, and exchange of researchers will spread excel-
lence and raise standards of research and patient care across 
Europe. The CML network and its activities provide the critical 
mass for added value and European leadership. The impact on 
the future management of CML patients is expected to be con-
siderable, since a rational advanced treatment design will likely 
lead to higher remission rates, longer survival and a higher pro-
portion of patients in which treatment can be permanently dis-
continued as an indicator of cure.
Myeloproliferative neoplasms
Introduction
The MPNs are disorders of HSC, and include polycythemia 
vera (PV), essential thrombocythemia (ET), prefibrotic and 
overt primary (PMF), and post-PV/post-ET myelofibrosis. These 
are chronic disorders usually affecting middle-advanced age 
patients; however, younger patients are now more frequently 
diagnosed thanks to greater awareness and broad availability of 
assays for MPN-associated driver mutations (JAK2V617F, JAK2 
exon12, MPL, and CALR mutation). The estimated annual 
incidence rate of MPN in RARECAREnet registry (http://www.
rarecarenet.eu) is 2.17 cases ×105/year; prevalence remains dif-
ficult to determine, but it is likely raising owing to improved 
management. MPN remain incurable diseases. While many 
patients with ET and PV display survival similar to control pop-
ulation, median survival in PMF is 6 years, although it may be 
improving following the introduction of ruxolitinib as standard 
of care. MPN patients suffer from major thrombotic events and 
hemorrhages. Quality of life is often impaired, most frequently 
in MF, due to a hyperinflammatory condition, responsible for 
disabling constitutional symptoms, and due to clonal cell prolif-
eration that causes cytosis, hepatosplenomegaly and extramed-
ullary hematopoiesis. A rapidly fatal, therapy-refractory, acute 
leukemia may develop in up to 15%–20% of all MPN.
European research contributions
The contribution of European scientists to basic, trans-
lational and clinical research is long standing and valuable. 
European researchers made the breakthrough discoveries of the 
JAK2V617F, JAK2 exon 12, and CALR mutations, which radi-
cally modified the understanding of MPN pathophysiology and 
revolutionized the WHO diagnostic criteria, to which European 
hemopathologists gave substantial contributions. Genetic hap-
lotypes predisposing to MPN were primarily discovered in 
Europe. The prognostic impact of driver and subclonal muta-
tions in MF was described by European researchers, in collabo-
ration with American colleagues, and promoted the development 
of new disease classification criteria and risk scores such as the 
MIPSS-70 score for PMF,37 the MySEC-PM score for secondary 
MF,38 the MTSS score for MF patients undergoing HSCT,39 and 
an integrated genomic score for all MPN.40 The IPSS and DIPSS 
score for MF were also products of research mostly done in 
Europe. European researchers were deeply involved in pivotal 
studies leading to the approval of the JAK1 and JAK2 inhibitors 
ruxolitinib and fedratinib,41–43 and more recently of ropeg-in-
terferon in PV44; several other ongoing clinical trials exploring 
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novel targeted therapies are leaded in Europe. Notably, fun-
damental studies conducted in Europe, that established new 
paradigms of clinical management, were investigator-initiated 
trials, such as: the ECLAP study, on low-dose aspirin in PV; the 
CytoPV trial, that established the optimal hematocrit target 
in PV; the PT-1 and the ANAHYDRET study, that compared 
hydroxyurea versus anagrelide for high-risk ET patients; a pro-
spective comparison of hydroxyurea plus aspirin with aspirin 
alone in younger patients with low-risk ET45; the low-PV trial 
with ropeg-interferon in low-risk PV. European researchers 
active in the MPN field refer to several national and supra-na-
tional (the ELN) networks that have produced popular guide-
lines, expert opinions, drug intolerance/resistance and treatment 
response criteria, and endpoints for novel drug studies.46 An 
European initiative (E-MPN network) connecting major centers 
involved in translational and clinical research has been launched 
recently with the aim to generate large bio-registries/biobanks. 
Strong, productive partnerships between European researchers 
and excellence research and clinical centers outside Europe, par-
ticularly in the United States, are well established.
Proposed research for the Roadmap
Fundamental questions on the molecular architecture of MPN 
remain unanswered: in about 20% of patients with ET and PMF 
the disease-initiating mutation remains unknown (“triple negative” 
patients); the relationships between the phenotype-driver muta-
tions and additional somatic mutations need to be defined in more 
detail (impact of the order of events); the genetic basis for familial 
clustering of MPN and, above all, the genetic events that under-
lie transformation of chronic MPN to aggressive acute leukemia 
need to be fully understood. Use of novel, high-throughput, sin-
gle-cell platforms, coupled with massive sequencing of noncoding 
regions, DNA methylation profiling, proteomic studies, targeted 
gene manipulation, and PDX, humanized animal models, will 
contribute to advancing our knowledge of MPN pathophysiology. 
Results from these basic/translational studies are predicted to have 
rapid and valuable impact on diagnosis, risk stratification, and 
novel therapeutic developments. We need criteria for categorizing 
patients, especially MF, according to their response to novel thera-
pies, to identify those who have the greatest chance to benefit from 
one drug, or drug combination, or conversely have poor or short-
term responses, and/or suffer from toxicities, thereby allowing early 
shift to alternatives. Since the JAK inhibitors are not curative, bet-
ter understanding of clonal cells’ abnormalities, cell-autonomous 
and microenvironment-directed signals, and host unique genomic 
signature, might all facilitate discovery of novel targets. Strategies 
to develop early interventions and possibly preventive measures 
in asymptomatic carriers of MPN-driven mutations (CHIP) need 
to be explored. Entirely new therapeutic approaches, including 
monoclonal antibodies and antigen-activated immune cells, are 
also worthwhile of being explored. Treatment of post-MPN acute 
leukemia represents an urgent unmet need. Preclinical and clinical 
studies might be fostered by reinforcing the existing networks of 
European researchers to share annotated patients’ samples, take 
advantage of new technologies and expertise, and facilitate patient 
referral for phase 1/2 clinical trials.
Anticipated impact of research
The great advances in understanding and managing MPN that 
happened in the last decade had profound impact on the patients’ 
journey, opened new avenues in cell and molecular biology and 
promoted the development of an entirely new class of agents as 
are the JAK inhibitors, that are finding unanticipated roles in dis-
eases far from MPN, such as the graft-versus-host disease, auto-
immune disorders and possibly COVID-19.47,48 The next steps 
are to use insights from population-derived studies to develop 
concepts and approaches for personalized medicine approach, 
ranging from refined diagnostic categories to alternative thera-
pies based on prediction of the individual benefit/risk ratio. This 
will not only impact favorably on the diseased individual, but 
may strengthen the relationships between European academy and 
the industry by fostering pharmaceutical research, and positively 
impact on patients’ families and the society in general by optimiz-
ing use of resources and improving individual work capabilities.
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